Skip to main content
Premium Trial:

Request an Annual Quote

There's an App for That?


The wait for cancer-screening test results can be "nerve-racking," says Technology Review's Jennifer Chu. But a new handheld device developed by researchers at Massachusetts General Hospital and Harvard Medical School could shorten the wait. The device plugs into a smart phone and can produce test results in an hour, Chu says. The tool takes a small tissue sample and analyzes it for cancer proteins. "When the latest prototype was tested on 50 patients with gastric-related cancer, it detected malignancies with 96 percent accuracy — better than existing laboratory-based tissue-sampling tests," Chu says. The study's results were published in Science Translational Medicine. The device reduced the possibility for human error, which could explain the efficiency and accuracy, the researchers say. It contains a microchip that houses a solution of magnetic nanoparticles, Chu says. The researchers identified 11 proteins commonly expressed by abdominal cancers and attached a corresponding ligand to each nanoparticle. "The device creates a magnetic field and uses it to determine which proteins had locked onto the nanoparticles. The device needs to detect only four out of the 11 proteins to achieve its 96 percent rate of accuracy, in a process that takes just about an hour," Chu adds.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.